Table 6

Cardiovascular considerations in treatment

Cardiovascular concernsTreatment considerations
STEMI and NSTEMIPrimary PCI vs thrombolytics
Myocardial injuryWorse prognosis, monitoring rising trends
Hypercoaulable stateThromboprophylaxis
ACEI or ARB useContinue treatment currently, await further studies
HCQ, CQ and/or azithromycin useQTc monitoring, avoid other QTc prolonging drugs
Immunosupression/ImmunomodulationMaybe helpful in selected patients with cytokine storm
MCSIABP and VA ECMO might be used for support in cardiogenic shock
  • ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; CQ, chloroquine; HCQ, hydroxychloroquine; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutanous coronary intervention; STEMI, ST-elevation myocardial infarction; VA ECMO, venoarterial extracorporeal membrane oxygenation.